Loss of MAFB in early T2D may promote β cell reprogramming; thus, understanding the stepwise transitions toward dysfunction, which are potentially reversible, may facilitate the production of therapies in which early β cell dysfunction can be targeted to slow the progression to overt diabetes. The gene discussed is MAFB; the disease is type 2 diabetes mellitus.